QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder
| Autor: | Melton B. Affrime, Andrej Skerjanec, Yibin Wang, Slavica Milosavljev, Denise Serra, Gerard Greig, Martin P. Bedigian |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyrrolidines Adolescent Genotype medicine.drug_class Torsades de pointes Placebo QT interval Dextromethorphan Electrocardiography Pharmacokinetics Moxifloxacin Internal medicine Darifenacin Medicine Humans Pharmacology (medical) Aged Benzofurans Pharmacology Receptor Muscarinic M3 Dextrorphan business.industry DNA Middle Aged medicine.disease Receptor antagonist Long QT Syndrome Phenotype Urinary Incontinence Overactive bladder Cytochrome P-450 CYP2D6 Anesthesia Cardiology Female business medicine.drug |
| Zdroj: | Journal of clinical pharmacology. 45(9) |
| ISSN: | 0091-2700 |
| Popis: | Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia (torsades de pointes). Darifenacin is a muscarinic M 3 selective receptor antagonist developed for the treatment of overactive bladder, a debilitating condition that is particularly prevalent in the older population. This 7-day, randomized, parallel-group study (n = 188) measured QT/QTc interval in healthy volunteers receiving once-daily darifenacin at steady-state therapeutic (15 mg) and supratherapeutic (75 mg) doses, alongside controls receiving placebo or moxifloxacin (positive control, 400 mg) once daily. There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at pharmacokinetic T m a x versus placebo were -0.4 and -2.2 milliseconds in the darifenacin 15 mg and 75 mg groups, respectively, compared with +11.6 milliseconds in the moxifloxacin group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text